论文部分内容阅读
胶质瘤在原发性脑肿瘤中发病率高且总体预后不良。目前胶质瘤的分级主要采用世界卫生组织（ WHO）中枢神经系统肿瘤分类中基于形态学的分类方法，但在临床中，组织学类型相同的个体其预后及对治疗的反应却不尽相同。分子标志物的出现可在WHO分类系统的基础上为胶质瘤定义新的亚型，且分子标志物的状态在某些胶质瘤亚型中具有良好的预后及预测价值，故分子分类方案表现出指导临床决策的潜力。“,”The incidence of glioma in primary brain tumors is high,and the prognosis is poor.The glioma grading is mainly based on the WHO classification of the central nervous system from the morphology.However, histologically identical tumors may have very different outcomes and responses to the treatment in clinical . The emergence of molecular markers is redefining tumor subtypes within each WHO category,and molecular markers status shows the prognostic and predictive value in certain subtypes of glioma ,so molecular classifi-cation has demonstrated the potential to guide the clinical decision .